mepolizumab asthma
Selected indexed studies
- Mepolizumab treatment in patients with severe eosinophilic asthma. (N Engl J Med, 2014) [PMID:25199059]
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (J Allergy Clin Immunol, 2023) [PMID:36538979]
- Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. (J Allergy Clin Immunol, 2025) [PMID:39521278]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2023) pubmed
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (2020) pubmed
- Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2022) pubmed
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. (2022) pubmed
- Mepolizumab treatment in patients with severe eosinophilic asthma. (2014) pubmed
- Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. (2025) pubmed
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. (2012) pubmed
- Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis. (2023) pubmed
- Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma. (2024) pubmed
- Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. (2023) pubmed